What Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) P/S Is Not Telling You

With a price-to-sales (or "P/S") ratio of 28x Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in the

Simply Wall StJun 13 08:30 ET

Express News | Rhythm Pharmaceuticals Grants Inducement Equity Covering 56,080 Shares To Ten New Employees

BenzingaJun 11 16:02 ET

CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $79

CCORF analyst Whitney Ijem maintains $Rhythm Pharmaceuticals(RYTM.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 50.0% and

moomoo NewsJun 5 08:31 ET

Rhythm Pharmaceuticals Presents Patient-reported Experiences With Hyperphagia in Hypothalamic Obesity at ENDO 2024

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R

GlobeNewswireJun 3 16:02 ET

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare

GlobeNewswireJun 3 08:02 ET

Global Market for Anti-Obesity Drugs Report, Featuring Altimmune, Currax Pharmaceuticals, Eli Lilly, F. Hoffmann-La Roche, Glaxosmithkline, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals and Vivus - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Market for Anti-obesity Drugs" report has been added to ResearchAndMarkets.com's offering.The report's scope includes an overview of the global market for anti-obe

BusinesswireMay 31 08:19 ET